The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future.

"Potential conflicts of interest. A. A. reports grants from AstraZeneca, Gilead Sciences, and ViiV Healthcare; consulting fees from AstraZeneca, Gilead Sciences, GSK, Janssen-Cilag, Merck, and ViiV Healthcare; and honoraria from AstraZeneca, Gilead Sciences, GSK, Janssen-Cilag, Merck, Pfizer, and ViiV Healthcare. M. B.-J. is an employee of Moderna, Inc., and may hold stock or stock options.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

"Potential conflicts of interest. A. A. reports grants from AstraZeneca, Gilead Sciences, and ViiV Healthcare; consulting fees from AstraZeneca, Gilead Sciences, GSK, Janssen-Cilag, Merck, and ViiV Healthcare; and honoraria from AstraZeneca, Gilead Sciences, GSK, Janssen-Cilag, Merck, Pfizer, and ViiV Healthcare. M. B.-J. is an employee of Moderna, Inc., and may hold stock or stock options. Notes: Acknowledgments. Medical writing and editorial assistance were provided by Ashlea Inan, PhD, and Emily Stackpole, PhD, of MEDiSTRAVA in accordance with Good Publication Practice (GPP 2022) guidelines, funded by Moderna, Inc., and under the direction of the authors.: Supplement sponsorship. This article appears as part of the supplement “COVID-19 Vaccination in the Immunocompromised Population,” sponsored by Moderna, Inc."